← Back to All US Stocks

CVRX Stock Analysis - CVRx, Inc. AI Rating

CVRX Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001235912
Recently Updated • Analysis: Mar 23, 2026 • SEC Data: 2025-12-31
AI Rating
SELL
85% Confidence

📊 CVRX Key Takeaways

Revenue: $56.7M
Net Margin: -94.1%
Free Cash Flow: $-40.8M
Current Ratio: 7.63x
Debt/Equity: 1.26x
EPS: $-2.04
AI Rating: SELL with 85% confidence

Investment Thesis

CVRx exhibits severe operational losses despite strong gross margins, indicating fundamental business model challenges beyond cost of goods sold. The company is heavily cash-dependent with negative free cash flow of -$40.8M and operating losses of -$51.3M, creating a runway concern even with substantial cash reserves of $75.7M. Revenue growth of 10.4% YoY is insufficient to justify the magnitude of operating losses and negative unit economics.

CVRX Strengths

  • + Exceptional gross margin of 85.3% demonstrates strong pricing power and product-market fit at the manufacturing level
  • + Robust cash position of $75.7M provides runway to reach profitability, reducing near-term liquidity risk
  • + Double-digit revenue growth of 10.4% YoY shows market adoption and demand for core products

CVRX Risks

  • ! Severe operating losses of -$51.3M with -90.5% operating margin indicate substantial costs in R&D, SG&A, or operations that are not scaling with revenue
  • ! Negative free cash flow of -$40.8M at current revenue levels means the business consumes cash even with positive gross profit, questioning path to sustainability
  • ! Cash burn rate of approximately -$40M+ annually combined with $49.5M long-term debt load suggests 1.5-2 year runway before cash depletion absent profitability inflection

Key Metrics to Watch

CVRX Financial Metrics

Revenue
$56.7M
Net Income
$-53.3M
EPS (Diluted)
$-2.04
Free Cash Flow
$-40.8M
Total Assets
$104.8M
Cash Position
$75.7M

💡 AI Analyst Insight

Strong liquidity with a 7.63x current ratio provides a solid financial cushion.

CVRX Profitability Ratios

Gross Margin 85.3%
Operating Margin -90.5%
Net Margin -94.1%
ROE -135.6%
ROA -50.9%
FCF Margin -71.9%

CVRX vs Healthcare Sector

How CVRx, Inc. compares to Healthcare sector averages

Net Margin
CVRX -94.1%
vs
Sector Avg 12.0%
CVRX Sector
ROE
CVRX -135.6%
vs
Sector Avg 15.0%
CVRX Sector
Current Ratio
CVRX 7.6x
vs
Sector Avg 2.0x
CVRX Sector
Debt/Equity
CVRX 1.3x
vs
Sector Avg 0.6x
CVRX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CVRX Balance Sheet & Liquidity

Current Ratio
7.63x
Quick Ratio
6.72x
Debt/Equity
1.26x
Debt/Assets
62.5%
Interest Coverage
-53.40x
Long-term Debt
$49.5M

CVRX 5-Year Financial Trend

CVRX 5-year financial data: Year 2021: Revenue $13.0M, Net Income -$14.1M, EPS N/A. Year 2022: Revenue $22.5M, Net Income -$43.1M, EPS $-4.16. Year 2023: Revenue $39.3M, Net Income -$41.4M, EPS $-2.02. Year 2024: Revenue $51.3M, Net Income -$41.2M, EPS $-1.99. Year 2025: Revenue $56.7M, Net Income -$60.0M, EPS $-2.65.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: CVRx, Inc.'s revenue has grown significantly by 335% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.65 indicates the company is currently unprofitable.

CVRX Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-71.9%
Free cash flow / Revenue

CVRX Quarterly Performance

Quarterly financial performance data for CVRx, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $13.4M -$12.9M $-0.49
Q2 2025 $11.8M -$14.0M $-0.57
Q1 2025 $10.8M -$13.8M $-0.53
Q3 2024 $10.5M -$9.0M $-0.43
Q2 2024 $9.5M -$11.7M $-0.56
Q1 2024 $8.0M -$11.4M $-0.55
Q3 2023 $6.2M -$9.0M $-0.43
Q2 2023 $5.0M -$11.1M $-0.54

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

CVRX Capital Allocation

Operating Cash Flow
-$40.2M
Cash generated from operations
Capital Expenditures
$580.0K
Investment in assets
Dividends
None
No dividend program

CVRX SEC Filings

Access official SEC EDGAR filings for CVRx, Inc. (CIK: 0001235912)

📋 Recent SEC Filings

Date Form Document Action
Mar 16, 2026 4 xslF345X05/form4-03162026_080309.xml View →
Mar 4, 2026 4 xslF345X05/form4-03042026_090343.xml View →
Mar 3, 2026 4 xslF345X05/form4-03032026_110335.xml View →
Mar 3, 2026 4 xslF345X05/form4-03032026_110358.xml View →
Mar 3, 2026 4 xslF345X05/form4-03032026_110313.xml View →

Frequently Asked Questions about CVRX

What is the AI rating for CVRX?

CVRx, Inc. (CVRX) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CVRX's key strengths?

Exceptional gross margin of 85.3% demonstrates strong pricing power and product-market fit at the manufacturing level. Robust cash position of $75.7M provides runway to reach profitability, reducing near-term liquidity risk.

What are the risks of investing in CVRX?

Severe operating losses of -$51.3M with -90.5% operating margin indicate substantial costs in R&D, SG&A, or operations that are not scaling with revenue. Negative free cash flow of -$40.8M at current revenue levels means the business consumes cash even with positive gross profit, questioning path to sustainability.

What is CVRX's revenue and growth?

CVRx, Inc. reported revenue of $56.7M.

Does CVRX pay dividends?

CVRx, Inc. does not currently pay dividends.

Where can I find CVRX SEC filings?

Official SEC filings for CVRx, Inc. (CIK: 0001235912) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CVRX's EPS?

CVRx, Inc. has a diluted EPS of $-2.04.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-12-31 | Powered by Claude AI